Valuation: Islet Holdings, Inc.

Market Cap 894K 785K 731K 672K 1.26M 85.44M 1.28M 8.67M 3.39M 42.38M 3.36M 3.29M 146M P/E 2000
-5.66x
P/E 2001 -3.18x
Enterprise Value 348K 306K 285K 262K 491K 33.28M 499K 3.38M 1.32M 16.5M 1.31M 1.28M 57.02M EV / Sales 2000
9.04x
EV / Sales 2001 23.1x
Free-Float
99%
Yield 2000 *
-
Yield 2001 -
Change 5-day change 1-year change 3-year change Capi.($)
+40.85%-.--% - - 21.3K
+0.61%+0.45%-8.97%-5.27% 13.56B
+0.24%-1.58%-29.45%-50.80% 5.16B
+0.39%+1.86%+2.81%+2.54% 4.9B
-0.84%-3.77%+0.36%-32.98% 4.1B
-1.49%-4.41%+1.56%-8.58% 3.63B
-1.86%-2.72%-2.40%-4.58% 3.6B
-1.19%-1.44%-3.14%+9.62% 3.47B
-1.82%-1.14%-14.08%-24.06% 2.43B
+0.63%+0.27%-2.30%+43.21% 1.87B
Average +3.55%-1.78%-6.18%-7.88% 4.75B
Weighted average by Cap. -0.27%-1.52%-7.28%-10.50%

Financials

2000 2001
Net sales 727K 638K 594K 546K 1.02M 69.43M 1.04M 7.05M 2.76M 34.43M 2.73M 2.67M 119M 637K 559K 520K 478K 897K 60.82M 912K 6.17M 2.42M 30.16M 2.39M 2.34M 104M
Net income -1.01M -887K -826K -759K -1.42M -96.53M -1.45M -9.8M -3.83M -47.87M -3.79M -3.71M -165M -3.42M -3M -2.8M -2.57M -4.82M -327M -4.91M -33.19M -12.99M -162M -12.85M -12.58M -560M
Net Debt 287K 252K 235K 216K 404K 27.41M 411K 2.78M 1.09M 13.6M 1.08M 1.05M 46.97M -546K -479K -446K -410K -769K -52.16M -783K -5.29M -2.07M -25.87M -2.05M -2.01M -89.38M
Logo Islet Holdings, Inc.
Islet Holdings Inc. is a biotechnology company, which is focused on cosmeceuticals. The Company is engaged in the research, development and commercialization of patented technologies in the field of transplantation in the therapy of people with conditions of insulin-dependent diabetes. The Company is developing intellectual property relating to hemp farming and extraction of cannabidiol (CBD) from hemp. Its technology constitutes methods for isolating, culturing, cryopreservation and immune-protection (microencapsulation) of islet cells. The Company's product candidates are intended for the treatment of insulin-dependent diabetes and are intended to be administered into the patient's abdominal cavity, where the transplanted islet cells will produce insulin in response to increase in blood glucose. The primary function of microencapsulation is to protect the islets from the host's immune system. The microcapsule coating is composed of layers of biocompatible materials.
Employees
-